| Revision as of 11:11, 3 December 2010 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:Wi← Previous edit |
Latest revision as of 08:04, 19 April 2024 edit undoM97uzivatel (talk | contribs)Extended confirmed users6,587 editsNo edit summary |
| (17 intermediate revisions by 16 users not shown) |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{Drugbox |
|
{{Drugbox |
|
| verifiedrevid = 400294135 |
|
| verifiedrevid = 400295046 |
|
| IUPAC_name = Magnesium 5-oxopyrrolidine-2-carboxylate |
|
| IUPAC_name = Magnesium 5-oxopyrrolidine-2-carboxylate |
|
| image = magnesium pidolate.png |
|
| image = magnesium pidolate.png |
|
|
|
|
|
<!--Clinical data--> |
|
|
| tradename = |
|
|
| Drugs.com = {{drugs.com|CDI|magnesium_pidolate}} |
|
⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
⚫ |
| pregnancy_category = |
|
⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
⚫ |
| legal_status = |
|
⚫ |
| routes_of_administration = |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
⚫ |
| bioavailability = |
|
⚫ |
| protein_bound = |
|
⚫ |
| metabolism = |
|
⚫ |
| elimination_half-life = |
|
⚫ |
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
⚫ |
| CAS_number = 135701-98-3 |
|
⚫ |
| ATC_prefix = A12 |
|
⚫ |
| ATC_suffix = CC08 |
|
⚫ |
| PubChem = 9838620 |
|
|
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
|
⚫ |
| DrugBank = |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID = 8014340 |
|
| ChemSpiderID = 8014340 |
|
|
| UNII_Ref = {{fdacite|correct|FDA}} |
|
| InChI = 1/2C5H7NO3.Mg/c2*7-4-2-1-3(6-4)5(8)9;/h2*3H,1-2H2,(H,6,7)(H,8,9);/q;;+2/p-2 |
|
|
|
| UNII = V5PC588N7G |
|
| InChIKey = JQAACYUZYRBHGG-NUQVWONBAS |
|
|
|
|
|
|
<!--Chemical data--> |
|
|
| C=10 | H=12 | N=2 | Mg=1 | O=6 |
|
| smiles = .C(=O)C1NC(=O)CC1.C(=O)C1NC(=O)CC1 |
|
| smiles = .C(=O)C1NC(=O)CC1.C(=O)C1NC(=O)CC1 |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| Line 12: |
Line 44: |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChIKey = JQAACYUZYRBHGG-UHFFFAOYSA-L |
|
| StdInChIKey = JQAACYUZYRBHGG-UHFFFAOYSA-L |
| ⚫ |
| CAS_number = |
|
| ⚫ |
| ATC_prefix = A12 |
|
| ⚫ |
| ATC_suffix = CC08 |
|
| ⚫ |
| PubChem = 9838620 |
|
| ⚫ |
| DrugBank = |
|
|
| chemical_formula = C<sub>10</sub>H<sub>12</sub>N<sub>2</sub>MgO<sub>6</sub> |
|
|
| molecular_weight = |
|
| ⚫ |
| bioavailability = |
|
| ⚫ |
| protein_bound = |
|
| ⚫ |
| metabolism = |
|
| ⚫ |
| elimination_half-life = |
|
| ⚫ |
| excretion = |
|
| ⚫ |
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| ⚫ |
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| ⚫ |
| pregnancy_category= |
|
| ⚫ |
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| ⚫ |
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| ⚫ |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| ⚫ |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
| ⚫ |
| legal_status = |
|
| ⚫ |
| routes_of_administration = |
|
|
}} |
|
}} |
|
|
|
|
|
'''Magnesium pidolate''', the ] ] of ] (pyroglutamic acid), is a ]. |
|
'''Magnesium pidolate''', the ] ] of ] (also known as pyroglutamic acid), is a ], which contains 8.6% magnesium w/w. |
|
|
|
|
|
==External links== |
|
==External links== |
|
* {{cite journal |author=De Franceschi L, Bachir D, Galacteros F, ''et al.'' |title=Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease |journal=Br. J. Haematol. |volume=108 |issue=2 |pages=284–9 |year=2000 |pmid=10691856 |doi=10.1046/j.1365-2141.2000.01861.x}} |
|
* {{cite journal |vauthors=De Franceschi L, Bachir D, Galacteros F, etal |title=Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease |journal=Br. J. Haematol. |volume=108 |issue=2 |pages=284–9 |year=2000 |pmid=10691856 |doi=10.1046/j.1365-2141.2000.01861.x|s2cid=36974114 |doi-access= }} |
|
|
|
|
|
{{Mineral supplements}} |
|
{{Mineral supplements}} |
|
|
|
| ⚫ |
] |
|
| ⚫ |
] |
|
|
|
|
|
|
|
|
{{gastrointestinal-drug-stub}} |
|
{{gastrointestinal-drug-stub}} |
|
⚫ |
] |
|
⚫ |
] |